CCLA Investment Management Sells 1,279,930 Shares of Edwards Lifesciences Co. (NYSE:EW)

CCLA Investment Management lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 99.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,395 shares of the medical research company's stock after selling 1,279,930 shares during the period. Edwards Lifesciences comprises approximately 1.8% of CCLA Investment Management's investment portfolio, making the stock its 27th biggest holding. CCLA Investment Management's holdings in Edwards Lifesciences were worth $107,036,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $34,000. Operose Advisors LLC raised its stake in shares of Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company's stock valued at $44,000 after acquiring an additional 452 shares in the last quarter. SRS Capital Advisors Inc. raised its stake in Edwards Lifesciences by 292.6% in the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company's stock worth $44,000 after buying an additional 474 shares in the last quarter. NBC Securities Inc. bought a new position in Edwards Lifesciences in the third quarter worth approximately $52,000. Finally, ORG Partners LLC bought a new position in Edwards Lifesciences in the third quarter worth approximately $66,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $1.76 during midday trading on Tuesday, reaching $86.46. The company had a trading volume of 2,119,569 shares, compared to its average volume of 3,662,030. The company has a market capitalization of $52.10 billion, a P/E ratio of 37.21, a P/E/G ratio of 3.65 and a beta of 1.10. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The firm's fifty day simple moving average is $90.06 and its 200-day simple moving average is $80.21. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares of the company's stock, valued at approximately $1,809,931.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Daveen Chopra sold 8,200 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $86.74, for a total transaction of $711,268.00. Following the completion of the transaction, the vice president now directly owns 22,750 shares in the company, valued at approximately $1,973,335. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The disclosure for this sale can be found here. Insiders have sold 213,340 shares of company stock valued at $18,816,952 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent research reports. Wells Fargo & Company boosted their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an "overweight" rating in a research note on Friday, April 26th. Oppenheimer boosted their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an "outperform" rating in a research note on Monday, March 18th. Citigroup upped their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 3rd. Deutsche Bank Aktiengesellschaft raised Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $86.00 to $103.00 in a research report on Tuesday. Finally, Stifel Nicolaus upped their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a "hold" rating in a research report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $93.88.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.